DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO
.....
Shortlist for the SCRIP Awards 2013.
http://www.scripintelligence.com/awards/categories/
Deciding on a shortlist from so many deserving entries was never going to be an easy process for our independent judging panel, but they rose to the challenge and this list represents the best of the best.
Best Company in an Emerging Market – Sponsored by Clinigen Group
- Bharat Biotech – India
- Dr Reddy’s Laboratories – India
- Sphaera Pharma – Singapore
- Sun Pharmaceutical Industries – India
- WuXi AppTec – China
Best Technological Development in Clinical Trials
- ArisGlobal’s Total Clinical
- Covance’s Xcellerate
- ICON’s ICONIK Monitoring for Patient Safety
- INC Research’s Trusted Process
- PPD’s real-time data offering
- Quintiles’ Infosario Safety
Best Partnership Alliance
- AstraZeneca with Bristol-Myers Squibb and Amylin in diabetes
- AstraZeneca and LegoChem to develop two compounds as a combination antibacterial
- Drugdev.org for The Investigator Databank with Janssen R&D, Eli Lilly, Merck & Co and Pfizer
- Roche with Isis Pharmaceuticals for antisense drugs in Huntington’s disease
- Vaxxas with Merck & Co for the Nanopatch vaccine platform
- WuXi AppTec with MedImmune for autoimmune and inflammatory diseases
Financing Deal of the Year
- Clinigen’s Initial Public Offering on AIM
- Elcelyx Therapeutics’ $20 million series C financing
- e-Therapeutics’ fundraising of £40 million on AIM
- Karolinska Development financing through option deal with Rosetta Capital Partners
- Mesoblast’s equity financing of Aus$170m
Best Advance in an Emerging Market
- Bharat Biotech’s development of low-cost rotavirus vaccine Rotavac for emerging markets
- Janssen’s TB treatment program for Sirtuto (bedaquiline) in emerging markets
- Novartis’s Jian Kang Kuai Che healthcare project in China
- Roche’s collaboration with Ascletis for hepatitis C treatments in China
Clinical Advance of the Year – Sponsored by Quintiles
- Galapagos’s Phase IIa study of the JAK1 inhibitor GLPG0634 in rheumatoid arthritis
- Genmab and Janssen Biotech’s Phase I/II study of daratumumab in multiple myeloma
- Janssen Research & Development/Merck’s PURSUIT clinical program of Simponi (golimumab) in ulcerative colitis
- Mundipharma’s (ReSearch Pharmaceutical Services) RELOXYN-Study of oxycodone/naloxone FDC for restless legs syndrome
- Novartis’s Gilenya’s effect on brain volume loss in TRANSFORMS, FREEDOMS and FREEDOMS II
- Regeneron Pharmaceuticals and Sanofi’s Phase IIa study dupilumab in in asthma
Licensing Deal of the Year
- Allergan and Molecular Partners for the development and commercialization of DARPin products for ophthalmic diseases
- AstraZeneca and Horizon Discovery for the development and commercialization of the HD-001 kinase target program for multiple cancer types
- Clinigen and Theravance for commercialization of Vibativ (telavancin) in Europe
- Genentech and AC Immune and for the development and commercialization of anti-Tau antibodies for Alzheimer’s disease
- Janssen Biotech and Genmab for the development and commercialization of daratumumab
- Pfizer and AstraZeneca for the over-the-counter marketing of Nexium (esomeprazole)
Executive of the Year
- Harvey Berger, chairman and chief executive officer of ARIAD Pharmaceuticals
- Joe Jimenez, chief executive officer of Novartis
- Josef von Rickenbach, chairman and chief executive officer of PAREXEL
- Patrik de Haes, chief executive officer of ThromboGenics
- Phil Lee, president and chief executive officer of PHT
- Roch Doliveux, chairman and chief executive officer of UCB
Biotech Company of the Year
- Ablynx
- ARIAD Pharmaceuticals
- Galapagos
- Genmab
- Prosensa
- ThromboGenics
Best Contract Research Organization
- ClinTec International
- Covance
- ICON
- INC Research
- PPD
- Quintiles
Management Team of the Year
- Beximco Pharmaceuticals’ management team
- Prosensa’s management team
- Regeneron Pharmaceuticals’ CEO Leonard S Schleifer and CSO George D Yancopoulos
Best New Drug – Sponsored by INC Research
- Algeta and Bayer’s Xofigo (radium Ra223 dichloride)
- ARIAD Pharmaceuticals’ Iclusig (ponatinib)
- Novartis’ Bexsero (meningococcal group B vaccine)
- ThromboGenics/Alcon’s Jetrea (ocriplasmin)
- Zealand Pharma’s Lyxumia (lixisenatide)
Pharma Company of the Year – Sponsored by ICON
- Amgen
- Astellas
- Dr Reddy’s Laboratories
- Sun Pharmaceutical Industries
- Vifor Pharma (Galenica)
New Drug Approvals 